Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder
- PMID: 8348503
- DOI: 10.1002/1097-0142(19930901)72:5<1743::aid-cncr2820720538>3.0.co;2-t
Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder
Abstract
Background: Transitional cell carcinoma (TCC) of the bladder is associated with alterations in the immune system of the host. The authors demonstrated that in patients with bladder carcinoma there is a negative correlation between the levels of natural killer (NK) activity and the clinical evolution and pathologic stages of disease.
Methods: The authors investigated the effect of various doses of recombinant interferon-alpha-2b (IFN-alpha-2b) for variable periods of culture on the nonmajor histocompatibility-restricted cytotoxic activity of peripheral blood mononuclear cells (PBMNC) with or without CD16 and CD3-depleted populations from patients with superficial (confined to the mucosa or lamina propria) and infiltrative (those infiltrating beyond the lamina propria) TCC of the bladder using 4-hour 51-sodium chromate (51Cr)-release cytotoxicity assays against both NK-sensitive (K562) and NK-resistant (JY) tumor target cells.
Results: The normal NK activity detected in PBMNC from patients with superficial TCC of the bladder can be significantly enhanced by short-term (18-hour) incubation with recombinant IFN-alpha (P < 0.05). The depressed NK cytotoxic activity found in PBMNC from patients with infiltrative TCC can also be significantly enhanced, but not normalized, by short-term (18-hour) incubation with recombinant IFN-alpha (P < 0.05). Short-term recombinant IFN-alpha-incubated PBMNC from patients with superficial, but not infiltrative, TCC of the bladder also showed marked cytotoxic activity against NK-resistant target cells. By selection with CD16 or CD3 monoclonal antibodies and complement, it was also found that the precursor and effector lymphocytes of this recombinant IFN-alpha-promoted cytotoxicity belong to NK lineage. In kinetic studies, it was found that the maximal levels of the recombinant IFN-alpha-promoted cytotoxic activity against NK-sensitive and NK-resistant target cells in PBMNC from patients with TCC were reached after 18 hours of culture.
Conclusion: Recombinant IFN-alpha can enhance the nonmajor histocompatibility-restricted cytotoxic activity of PBMNC from patients with TCC of the bladder.
Similar articles
-
Interferon beta enhances the natural killer activity of patients with bladder carcinoma.Cancer Immunol Immunother. 1994 Jun;38(6):406-10. doi: 10.1007/BF01517211. Cancer Immunol Immunother. 1994. PMID: 8205562 Free PMC article.
-
Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.Cancer. 1995 Jun 1;75(11):2720-6. doi: 10.1002/1097-0142(19950601)75:11<2720::aid-cncr2820751114>3.0.co;2-4. Cancer. 1995. PMID: 7743476
-
Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder.Int J Immunopharmacol. 1993 Apr;15(3):335-41. doi: 10.1016/0192-0561(93)90044-y. Int J Immunopharmacol. 1993. PMID: 8505146
-
Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder.Eur Urol. 1991;19(1):74-8. doi: 10.1159/000473584. Eur Urol. 1991. PMID: 2007423
-
Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder.Anticancer Drugs. 1992 May;3 Suppl 1:5-8. doi: 10.1097/00001813-199205000-00002. Anticancer Drugs. 1992. PMID: 1611117
Cited by
-
Interferon beta enhances the natural killer activity of patients with bladder carcinoma.Cancer Immunol Immunother. 1994 Jun;38(6):406-10. doi: 10.1007/BF01517211. Cancer Immunol Immunother. 1994. PMID: 8205562 Free PMC article.
-
The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients.Oncoimmunology. 2019 Aug 20;8(11):e1652538. doi: 10.1080/2162402X.2019.1652538. eCollection 2019. Oncoimmunology. 2019. PMID: 31646098 Free PMC article.
-
Immune checkpoint blockade and interferon-α in melanoma.Semin Oncol. 2015 Jun;42(3):436-47. doi: 10.1053/j.seminoncol.2015.02.012. Epub 2015 Feb 14. Semin Oncol. 2015. PMID: 25965362 Free PMC article. Review.
-
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.Clin Cancer Res. 2019 Jan 15;25(2):524-532. doi: 10.1158/1078-0432.CCR-18-2258. Epub 2018 Nov 12. Clin Cancer Res. 2019. PMID: 30420448 Free PMC article. Clinical Trial.
-
Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.J Immunother Cancer. 2018 Oct 23;6(1):112. doi: 10.1186/s40425-018-0428-5. J Immunother Cancer. 2018. PMID: 30352626 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical